REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 124 participants.

Also called NCT07006493

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 124 participants (planned count) (from the registry)
Sponsor
SuZhou Sinus Medical Technologies Co.,Ltd (from the registry)
Registry
  • NCT NCT07006493
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07006493. Randomized; double masking; primary purpose treatment. Start 2025-07-20 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
Acronym
REFINE-HCM
Condition
Hypertrophic Cardiomyopathy, Obstructive
Intervention (Device)
Transcatheter Intramyocardial Septal Radiofrequency Ablation System
Lead sponsor
SuZhou Sinus Medical Technologies Co.,Ltd (class: industry)

Record details

Record id
cardio:ct-nct07006493
Content hash
8f26e4b62a89e860cd4e15cf53d0d062749f6dd362169c8abe129844532c9ba3